Evaluation of Early Administration of Insulin Glargine in the Acute Management of Diabetic Ketoacidosis

Curr Diabetes Rev. 2021;17(8):e030221191986. doi: 10.2174/1573399817666210303095633.

Abstract

Background: Few studies have evaluated the early use of insulin glargine in the management of diabetic ketoacidosis (DKA) patients. Early insulin glargine use in DKA was safe and associated with a trend towards faster DKA resolution.

Objectives: To evaluate the efficacy and safety of early insulin glargine administration for acute management of DKA in critically ill patients.

Methods: This single-center retrospective cohort study included patients, who were >18 years of age with DKA, admitted to the intensive care unit (ICU) for at least 12 h, and received intravenous insulin infusion for at least 6 h. The primary endpoint was the association between the time to insulin glargine administration and time to DKA resolution. Linear and logistic regression analyses were performed.

Results: Of the 913 patients evaluated, 380 were included in the study. The overall mean age was 45±17 years, 196 (51.6%) were female, and 262 (70%) patients had type 1 diabetes mellitus. The mean blood glucose level was 584.9±210 mg/dL, pH was 7.16±0.17, anion gap was 28.17±6.9 mEq/L, and serum bicarbonate level was 11.19±5.72 mEq/L. Every 6-h delay in insulin glargine administration was associated with a 26-min increase in time to DKA resolution (95% confidence interval [CI], 14.76-37.44; p<0.0001), 3.2-h increase in insulin infusion duration (95% CI, 28.8-36; p<0.0001), and 6.5-h increase in ICU LOS (95% CI, 5.04-7.92; p<0.0001).

Conclusion: Early administration of insulin glargine is potentially safe and may be associated with a reduction in time to DKA resolution and a shorter duration of insulin infusion.

Keywords: Diabetes mellitus; blood glucose; diabetic ketoacidosis; insulin; insulin glargine; length of stay; retrospective study..

MeSH terms

  • Adult
  • Diabetes Mellitus, Type 1* / drug therapy
  • Diabetic Ketoacidosis* / drug therapy
  • Female
  • Humans
  • Insulin / adverse effects
  • Insulin Glargine / adverse effects
  • Middle Aged
  • Retrospective Studies

Substances

  • Insulin
  • Insulin Glargine